R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL
To compare the efficacy and safety of chemotherapy alone and combined modality therapy in the treatment of localized CD20 (+) diffuse large B-cell lymphoma
Diffuse Large B-cell Lymphoma
DRUG: R-CHOP|RADIATION: Radiotherapy
To compare 3-year event-free survival, definition of events: failure to achieve CR after completion of planned 1st-line treatment, progression of disease, relapse, institution of a new anticancer treatment or any cause of death) rate in patients with CD20 (+) diffuse large B-cell lymphoma treated with either R-CHOP chemotherapy alone or R-CHOP plus radiotherapy, 3 years
To evaluate and compare OS between the two arms, 3 years|To evaluate and compare the ORR and CR rate, after completion of treatment|To evaluate and compare disease-free survival (DFS), 3 years|To evaluate treatment-failure pattern, 3 years|Number of Participants with Adverse Events in each arm, 3 years|To assess patient-reported outcomes (PROs) in both arms, 3 years|A role of interim PET after 3 cycles of R-CHOP chemotherapy: correlation with PFS and OS, 3 years
To compare the efficacy and safety of chemotherapy alone and combined modality therapy in the treatment of localized CD20 (+) diffuse large B-cell lymphoma